Nav: Home

New clinical trial shows second generation drug-eluting stents are safe and effective

April 26, 2018

SAN DIEGO, April 26, 2018 - Results of the PERSPECTIVE trial were presented today as late-breaking clinical science at the Society for Cardiovascular Angiography and Interventions (SCAI) 2018 Scientific Sessions. The PERSPECTIVE study is a prospective, single-center rigorously performed clinical trial and reports on one-year outcomes of patients undergoing chronic total occlusion (CTO) percutaneous coronary intervention (PCI) treated with Zotarolimus-Eluting Stents (ZES). The ZES included in the study were manufactured by Medtronic and represent a modern, newer generation drug-eluting stent (DES).

CTO is a complete blockage of one or more coronary arteries that has been present for at least three months and occurs in 20 percent of patients with coronary artery disease (UVA Health). CTO PCI has become the preferred treatment option for complex, high-risk patients due to improvements in equipment and novel procedural techniques. There is limited data on procedural and long-term safety and efficacy of CTO revascularization applying modern techniques with newer generation DES.

The PERSPECTIVE trial examined procedural, clinical and health status outcomes using contemporary methods and was reviewed by an independent core laboratory and events committee. Among consecutive patients undergoing attempted CTO PCI, procedural and in-hospital clinical outcomes were examined in addition to major adverse cardiac events (MACE) - death, myocardial infarction and target lesion revascularization. In a pre-specified cohort of prospectively followed patients, quality of life was measured at baseline and one-year. A one-year MACE analysis of patients treated with ZES was compared to a pooled analysis of historical DES trials.

The study included 183 patients with successful CTO recanalization and treatment with ZES. Successful guidewire achievement of at least TIMI 2 flow was observed in 93.4 percent of patients. Compared with performance goals from prior CTO DES trials (1-year MACE, 25.2 percent), treatment with ZES was associated with significantly lower occurrence of adverse events (7.6 percent). One-year rates of myocardial infarction and target lesion revascularization were 3.5 percent and 1.7 percent, respectively. Patients reported significant improvement to quality of life from baseline to one-year (Seattle Angina Questionnaire, 72.3 ± 26.3 versus 96.3 ± 10.2).

"Our study is the most comprehensive review of the safety, efficacy and durability of contemporary stent techniques with ZES for a high-lesion, complex patient population," said lead author David Kandzari, MD, Piedmont Heart Institute in Atlanta, GA. "Not only were the success rates favorable but we were also able to demonstrate that patients reported an improved quality of life, which should be considered one of the most important outcomes of any procedure."

The authors of the study note the FDA is currently reviewing this study data for a potential expanded label indication for the ZES (Medtronic).
-end-
Session Details:

"Late-Breaking Clinical Science I: Procedural, Clinical and Health Status Outcomes in Chronic Total Coronary Occlusion Revascularization with Zotarolimus-Eluting Stents: Results from the PERSPECTIVE Trial" [April 26, 2018, 11:00 a.m. - 12:00 p.m. PDT, Seaport DE]

About SCAI

The Society for Cardiovascular Angiography and Interventions is a 4,200-member professional organization representing invasive and interventional cardiologists in approximately 75 nations. SCAI's mission is to promote excellence in invasive/interventional cardiovascular medicine through physician education and representation, and advancement of quality standards to enhance patient care.

For more information about the SCAI 2018 Scientific Sessions, visit http://www.scai.org/SCAI2018/Default.aspx.

Society for Cardiovascular Angiography and Interventions

Related Myocardial Infarction Articles:

Discovery of cells that heal cardiac damage after infarction
Researchers at Cima and the Clinica Universidad de Navarra (Spain) have led an international study identifying the cardiac cells responsible for repairing the damage to this organ after infarction.
CHOP researchers find MIS-C associated with myocardial injury
Using sensitive parameters to assess cardiac function, researchers at Children's Hospital of Philadelphia (CHOP) have found that cardiac involvement in multisystem inflammatory syndrome in children (MIS-C) differs from Kawasaki disease (KD) and is associated with myocardial injury.
Heart attack modeled with human stem cells
A model of ischemic heart disease was developed using human induced pluripotent stem cells (hiPSC).
The relationship between lifetime drinking and non-fatal acute myocardial infarction
New research from the Prevention Research Center of the Pacific Institute for Research and Evaluation suggests that the impact of alcohol consumption on coronary heart disease may be underestimated.
The relationship between mean platelet volume and in-hospital mortality in geriatric patients with ST segment elevation myocardial infarction who underwent primary percutaneous coronary intervention
In the current issue of Cardiovascular Innovations and Applications volume 4, issue 2, pp.
Epicardial coronary artery abnormalities that do not result in myocardial ischemia
What to Do with Epicardial Coronary Artery Abnormalities That do not Result in Myocardial Ischemia?
Dose-dependent effects of esmolol-epinephrine combination therapy in myocardial ischemia
Animal studies on cardiac arrest found that a combination of epinephrine with esmolol attenuates post-resuscitation myocardial dysfunction.
Renal infarction is associated with acute kidney injury in patients with cardiac amyloidosis
Systemic amyloidosis is a major cause of renal injury, mostly due to direct kidney damage caused by deposits of abnormal protein called amyloid, in the kidney parenchyma.
Anesthetic-induced myocardial conditioning: Molecular fundamentals and scope
The objective of this study was to investigate the role that miRNAs play in the cardioprotective effect of halogenated anesthetics.
A role for circadian enhancers to prevent myocardial injury in the perioperative setting
The current study demonstrates a deleterious effect of midazolam administration prior to myocardial ischemia and reveals reduced circadian protein Period 2 (PER2) levels as the underlying mechanism.
More Myocardial Infarction News and Myocardial Infarction Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: The Power Of Spaces
How do spaces shape the human experience? In what ways do our rooms, homes, and buildings give us meaning and purpose? This hour, TED speakers explore the power of the spaces we make and inhabit. Guests include architect Michael Murphy, musician David Byrne, artist Es Devlin, and architect Siamak Hariri.
Now Playing: Science for the People

#576 Science Communication in Creative Places
When you think of science communication, you might think of TED talks or museum talks or video talks, or... people giving lectures. It's a lot of people talking. But there's more to sci comm than that. This week host Bethany Brookshire talks to three people who have looked at science communication in places you might not expect it. We'll speak with Mauna Dasari, a graduate student at Notre Dame, about making mammals into a March Madness match. We'll talk with Sarah Garner, director of the Pathologists Assistant Program at Tulane University School of Medicine, who takes pathology instruction out of...
Now Playing: Radiolab

What If?
There's plenty of speculation about what Donald Trump might do in the wake of the election. Would he dispute the results if he loses? Would he simply refuse to leave office, or even try to use the military to maintain control? Last summer, Rosa Brooks got together a team of experts and political operatives from both sides of the aisle to ask a slightly different question. Rather than arguing about whether he'd do those things, they dug into what exactly would happen if he did. Part war game part choose your own adventure, Rosa's Transition Integrity Project doesn't give us any predictions, and it isn't a referendum on Trump. Instead, it's a deeply illuminating stress test on our laws, our institutions, and on the commitment to democracy written into the constitution. This episode was reported by Bethel Habte, with help from Tracie Hunte, and produced by Bethel Habte. Jeremy Bloom provided original music. Support Radiolab by becoming a member today at Radiolab.org/donate.     You can read The Transition Integrity Project's report here.